Clinical Trial Update: Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial of belimumab for diffuse cutaneous systemic sclerosis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: Hospital for Special Surgery, New York | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2022-05-24